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The inclusion of pharmacists into general practices in Australia has expanded in recent
years. This systematic review aimed to synthesise the literature of qualitative and quantita-
tive studies, and identify the knowledge gaps, related to pharmacists working in general
practice in Australia.
Methods
This systematic review followed the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses guidelines. PubMed, EBSCOhost, EMBASE, and the Cochrane Library
were searched from the inception of databases to January 2021. The search was focused
on studies investigating general practice pharmacists in Australia. The quality of each study
was appraised using the Mixed Method Appraisal Tool criteria. The narrative synthesis
approach was utilised to describe data due to the heterogeneity among study designs and
measures.
Results
Twenty-five studies were included in this review. General practice pharmacists engaged in
various non-dispensing patient care services, with medication management reviews being
the primary activity reported. General practice pharmacists’ characteristics and an environ-
ment with a willingness of collaboration were the notable influencing factors for successfully
including pharmacists in general practices. Factors that posed a challenge to the adoption
of general practice pharmacists were lack of funding and other resources, poorly defined
roles, and absence of mentoring/training.
Conclusion
This review has summarised the characteristics, activities, benefits, barriers, and facilitators
of including pharmacists in general practices in Australia. General practice pharmacists are
well accepted by stakeholders, and they can engage in a range of patient-centred activities
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to benefit patients. There is a need for more robust research to explore the patient and eco-
nomic outcomes related to clinical activities that a pharmacist can perform in general prac-
tice, as a foundation to developing an appropriate and sustainable funding model. The
findings of this review will be beneficial for pharmacists, researchers, policymakers, and
readers who wish to implement the role of general practice pharmacists in the future.
Introduction
With the expansion of pharmacists’ roles, pharmacists have been included in primary health-
care teams to provide collaborative patient care in many countries. The co-location of pharma-
cists within primary healthcare teams has been studied in the United States of America (USA),
United Kingdom (UK), Canada, Australia, The Netherlands, Ireland, Brazil, New Zealand,
and Malaysia [1–8]. Studies from the USA, UK, and Canada have reported that the inclusion
of pharmacists into primary healthcare teams has improved patients’ health outcomes and
benefited patients in other ways [9–11].
The primary purpose of co-locating pharmacists in primary care teams is to improve medi-
cines optimisation and patient safety [2,12,13]. However, the characteristics of models for
including pharmacists into primary care vary according to the challenges and policies of
healthcare systems in individual countries. For example, in the USA, the Patient-Centred Med-
ical Home (PCMH) model was introduced to improve the quality of patient-centred services
in primary healthcare and to lower healthcare costs [14]. The PCMH model relies on critical
structural components, such as the shared use of health information, advanced performance
indicators, trust and good rapport among providers and patients, and adequate financial reim-
bursement [15]. The PCMH model has offered numerous opportunities for pharmacists to
contribute through diverse clinical activities to improve patient outcomes [10,16,17].
Canadians have investigated the inclusion of pharmacists into family practices since 2003.
The “Integrating Family Medicine and Pharmacy to Advance Primary Care Therapeutics
(IMPACT)” project was one of the largest trials launched in Ontario, Canada to investigate the
inclusion of pharmacists in family health teams [18]. The main aim was to improve collabora-
tive practice between pharmacists, family physicians, and allied health professionals in manag-
ing medication therapy [18–21]. In Canada, the public health system has provided funding for
pharmacists in family health teams and pharmacists have rights to prescribe in some states/
provinces [22,23]. Canadian studies have reported positively on patient-centred activities as a
result of including pharmacists as a part of the primary care team [9,12,21]. Furthermore,
there is evidence for continued expansion of pharmacists in family health teams across the
country [20].
National Health Service England launched the Clinical Pharmacists in General Practice
model in 2015 to help overcome the expanding workforce crisis of general practitioners (GPs)
[11]. The over-arching purpose of including pharmacists into general practices across the UK
is to improve patient care [13,24,25]. This includes providing extra help to manage chronic
health conditions, education to those on multiple medicines, and better access to health assess-
ments [25]. UK studies have shown that general practice pharmacists’ consultations can bene-
fit patients [11,24–27]. There are currently over 1000 full-time equivalent clinical pharmacists
working across general practices in the UK [28]. Like in Canada, pharmacists in general prac-
tices in the UK are funded by the government, and they have rights to prescribe [29]. The
“Pharmacotherapy Optimisation through Integration of a Non-dispensing pharmacist in a
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primary care Team (POINT)” study in The Netherlands [5] and the “General Practice Pharma-
cist (GPP)” study in Ireland [4] were another two projects launched to explore the general
practice pharmacist model.
In Australia, general practices are the frontline healthcare service that act as a gateway to
specialist services [30]. The inclusion of pharmacists in Australian general practices has been
evolving gradually over the last decade to provide non-dispensing services such as medication
management services, medication safety initiatives, and patient education. The role of general
practice pharmacists has been supported by the Australian Medical Association (AMA), Phar-
maceutical Society of Australia (PSA), and various Primary Health Networks in Australia since
2015 [31]. However, Australia lags well behind other countries, such as the UK and Canada, in
widening the role of general practice pharmacists across the country [32]. The reasons may be
due to unique challenges and policies in the Australian healthcare system, including the lack of
an appropriate funding model, limitation of prescribing rights in the scope of practice of phar-
macists, and the absence of focusing on overall patient health outcomes when considering the
remuneration [33]. Australia has a growing burden of chronic diseases, an increased ageing
population, health workforce pressures, unacceptable inequities in health outcomes and access
to services, and escalating healthcare expenditure [34,35]. It is still unknown whether there is
any impact on these healthcare system challenges with the inclusion of pharmacists in Austra-
lian general practice.
There have been systematic reviews conducted globally to explore the effectiveness of the
activities of pharmacists in general practices [36]; to investigate how the degree of inclusion of
a non-dispensing pharmacist impacts medication-related health outcomes in primary care
[37]; and to assess the competencies of general practice pharmacists [38]. However, to date,
there has not been a review to assess the overall impact of the inclusion of pharmacists in Aus-
tralian general practices. Even though there have been studies conducted in Australia related
to general practice pharmacists [32,39–62], the literature has not been summarised to describe
the role of general practice pharmacists and to identify knowledge deficits related to pharma-
cists working in general practice in Australia.
The aim of this systematic review was to synthesise the literature related to general practice
pharmacists in Australia, and attempt to answer the following research questions:
1. What are the clinical and non-clinical activities being conducted by pharmacists in general
practices in Australia?
2. What are the benefits/outcomes from the inclusion of pharmacists in the Australian general
practice setting?
3. What are the perspectives of stakeholders, and the barriers and facilitators of the inclusion
of pharmacists in the general practice setting in Australia?
4. What are the characteristics, qualifications, and experience of the pharmacists in general
practices in Australia?




A systematic review for mixed methodologies was followed, informed by the Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses (PRISMA) systematic review guidelines
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and checklist (S1 Checklist) [63,64]. A mixed-methods systematic review methodology was
employed due to the relative paucity of research on the general practice pharmacist model in
Australia. This approach provided the flexibility required to incorporate various study meth-
odologies and offered a systematic design to conduct the literature review to meet the aims of
the research. The review was registered with the international database of prospectively regis-
tered systematic reviews (PROSPERO: CRD42019109963).
Literature search strategy
A systematic literature search of PubMed, EBSCOhost, EMBASE, and the Cochrane Library
was conducted from the inception of each database to January 2021. The search was focused on
studies investigating general practice pharmacists in Australia. Full text peer-reviewed English
language articles that involved qualitative, quantitative or mixed-method studies with any out-
comes reported were included in the review. Search strategies for databases are provided in S1
Table. A manual search of the bibliography in the reference lists of identified articles was con-
ducted and other related review articles were screened for additional relevant studies.
Eligibility criteria
Articles were included in the review if the following conditions were met: (a) tested an inter-
vention of pharmacists in general practice and/or obtained views of stakeholders (pharmacists,
GPs, practice staff and patients) related to pharmacist services/activities in general practice;
and (b) a pharmacist was co-located within a general practice clinic to provide non-dispensing
medication-related activities.
Articles were excluded if any of the following conditions were met: (a) conducted in sec-
ondary, tertiary or other care settings (hospitals, nursing homes); (b) conducted outside of
Australia; or (c) presented as editorials, protocols, letters, commentaries, and reviews.
Data evaluation
Abstract and full-text screening was performed by two authors (TS, JT), who independently
applied the eligibility criteria to 10% of the search results and checked inter-rater reliability.
After finding 100% agreement, a single investigator (TS) rated the remaining 90% articles
alone [65,66]. Full texts were reviewed where a decision could not be made on abstract and
title alone. Title and abstract screening was conducted by using the software package Covi-
dence for conducting systematic reviews [67]. Full-text screening involved using EndNote to
manage and retrieve full-texts.
Quality appraisal
The Mixed Methods Appraisal Tool (MMAT) was used to appraise the quality of empirical
studies, as it covers a variety of methodologies [68]. The MMAT includes five core quality cri-
teria for each of the following five categories of study designs: qualitative research, randomised
controlled trials, non-randomised studies, quantitative descriptive studies, and mixed-method
studies [68]. Critical appraisal of methodological quality and risk of bias assessment of
included papers were undertaken independently by two reviewers (TS, SK). A third reviewer
(MN) was consulted in the case of disagreement without reaching consensus.
Data analysis
A narrative synthesis approach was used to synthesise the findings of the included articles, due
to the heterogeneity of studies in the review with a range of methodologies [69,70]. First, a
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preliminary synthesis was conducted to search studies, and present results in a tabular form.
Then the results were discussed by two reviewers (TS, SK) and structured into themes. The
studies included in the narrative synthesis were then summarised within a framework to cap-
ture the features of each study with reference to the focus of this review: clinical and non-clini-
cal activities of general practice pharmacists; benefits of general practice pharmacists;
perspectives of stakeholders about general practice pharmacists; barriers and facilitators for
the implementation of general practice pharmacists; and characteristics and training require-
ments of general practice pharmacists. Original investigators of the studies were contacted to
obtain additional research information related to the framework [71].
Results
Literature retrieval
A search of the databases identified 2215 records once duplicates were removed. Twenty-five
articles met the full inclusion criteria and were included in this review [32,39–62]. Fig 1 shows
the flow diagram of the study selection.
Article characteristics
Characteristics of the 25 articles included in this review are provided in S2 Table. The included
articles aimed to: (i) characterise the clinical and non-clinical activities that a pharmacist can
perform in general practice [32,39,42,44,46,51–53,55,56,62], (ii) explore the pharmacist recom-
mendations and general practitioner acceptance rates regarding medication-related decision-
making in general practice [43,49–51], and (iii) explain the stakeholders’ perspectives, barriers
and facilitators of the inclusion of a pharmacist into general practice [40,41,45,47,48,51,54,57–
59,61]. The included articles utilised designs that were qualitative (40%, n = 10)
[40,42,45,47,48,55,58,59,61,62], quantitative non-randomised control (32%, n = 8)
[39,43,46,49,50,52,56,60], quantitative descriptive (8%, n = 2) [32,41], and mixed-method
(20%, n = 5) [44,51,53,54,57].
Risk of bias and quality assessment
All the included articles met the following screening criteria of MMAT: having clear research
questions and addressing the research questions based on the collected data [65]. Almost all
articles (92%, n = 23) were rated average or above average quality (S3 Table). Only 5 articles
that utilised a qualitative design fulfilled all the criteria in the MMAT [44,46,47,58,60]. The
articles which utilised a quantitative non-RCT design (32%, n = 8) or a mixed-method design
(20%, n = 5) fulfilled 2–4 criteria [39,43,44,46,49–54,56,57,60], and quantitative descriptive
design (8%, n = 2) fulfilled 3–4 criteria in the MMAT [31,40]. Overall, five articles (20%) ful-
filled all criteria [44,46,47,59,61], eight articles (32%) fulfilled 4 criteria
[32,40,42,46,49,50,54,62], ten articles (40%) fulfilled 3 criteria [39,41,52,52,54–58,60], and two
articles (8%) fulfilled 2 criteria [42,43] for their particular research design using the MMAT.
Details of the quality appraisal of the included articles are provided in S3 Table.
All the articles which utilised a qualitative design (n = 10, 40%) fulfilled 3 criteria or more
in the MMAT. Among the ten qualitative studies, five studies used semi-structured interviews
[45,46,58,59,61], two studies used a combination of semi-structured and focus group inter-
views [40,47], two were case studies [55,62], and one study used an ethnographic approach
[42]. Thematic analysis (6 out of 10, 60%) was the most widely used qualitative analysis
method [45,47,48,58,59,61]. In the majority of non-randomised quantitative components and
mixed-method studies, confounders and inconsistencies were not accounted for in the design
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and analysis. Small sample size/low response rate, lack of a control group, non-probability
nature of sampling and researcher bias were the most notable limitations in the included arti-
cles [32,39–44,46,49–58,60,62].
Synthesis of results
Clinical/Non-clinical activities conducted by the pharmacists in general practices and
outcomes. The general practice pharmacist role comprised a variety of activities including
medication reviews and reconciliation; clinical audits; adherence counselling; patient
Fig 1. Flowchart depicting inclusion/exclusion.
https://doi.org/10.1371/journal.pone.0258674.g001
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education on medical conditions and medications; reviewing and ordering of laboratory tests;
healthy lifestyle advice; chronic disease management; medication information provision; and
administrative work [32,40,42,44,46,48–53,55–57]. Medication management reviews per-
formed by general practice pharmacists has been the leading clinical activity investigated in
most articles, reflecting its role as the primary source of funding for Australian general practice
pharmacists at present [32,39,43,46,49–51,62].
The inclusion of pharmacists into general practices can facilitate the delivery of multiple
patient-centred activities to manage chronic diseases; however, there were only five studies
demonstrating clinical outcomes for patients [44,53,55,56,62]. Two articles reported general
practice pharmacists’ activities related to osteoporosis and asthma management in general
practice [44,53]. Pharmacist-led consultations made significant improvements to the prescrip-
tion of anti-osteoporosis medicines, vitamin D and calcium supplements in general practice
[44]. A pilot study demonstrated the feasibility, acceptability, and benefits of a general practice
pharmacist in asthma management [53]. This study showed that general practice pharmacists
engaged in the following activities to manage asthma: performing asthma control assessment,
making recommendations to adjust medication or device, providing education on correct
device use and avoidance of trigger factors, and developing an asthma action plan [53]. Case
studies and qualitative data from the study indicated potential hospital admission avoidance
and stakeholder acceptability of asthma management by a general practice pharmacist [53].
Two articles reported the perspectives of community pharmacists and GPs on collaborative
asthma management with general practice pharmacists [58,59]. The articles indicated that
community pharmacists and GPs supported collaborative asthma management with general
practice pharmacists [58,59]. Furthermore, these two articles illustrated the challenges in
asthma management, barriers and facilitators for collaborative asthma management, and pos-
sible collaborative asthma care models with general practice pharmacists [58,59].
Three separate studies reported smoking cessation sessions, deprescribing in older persons,
and reviewing medications in Human Immunodeficiency Virus (HIV)-infected patients utilis-
ing general practice pharmacists [55,56,62]. A pilot study reported that there was a smoking
self-reported abstinence rate of 30% (20/66) and a verified abstinence rate of 20% (13/66) after
at least 6 months, due to smoking cessation sessions conducted by a general practice pharma-
cist [56]. A case study report showed that deprescribing in older patients by general practice
pharmacists could increase medication safety of elderly patients in general practices [55]. One
case study demonstrated that review of medications by a general practice pharmacist could
improve patient outcomes and prevent long-term consequences in patients with HIV [62].
Further, several studies have described other potential roles for general practice pharmacists:
prescribing, managing insomnia, providing specialised medication information to GPs,
screening for undiagnosed diseases, on-site dispensing, and optimising medication records
[32,40–42,48,51,52,57,61].
Benefits of pharmacists in general practices. The inclusion of pharmacists in general
practices can increase communication and collaboration between pharmacists and GPs
[32,40,41,47,48,51,52,54,57,58]. The included articles reported that collaborative interventions
by general practice pharmacists can identify and resolve medication-related problems
[43,46,50,52,55,62]. For example, Benson et al in 2018 reported that general practice pharma-
cists identified 1124 medication-related problems from 15 general practices in Western Sydney
over six months [50]. Tan et al reported that the median number of medication-related prob-
lems per patient identified by a general practice pharmacist at baseline was 2, decreasing to
zero at six months after general practice pharmacists’ interventions [46]. Two studies have
reported that general practice pharmacists’ consultations can improve the medication adher-
ence of patients in general practices [46,49]. One study indicated that general practice
PLOS ONE General practice pharmacists in Australia
PLOS ONE | https://doi.org/10.1371/journal.pone.0258674 October 14, 2021 7 / 19
pharmacist’s consultations improved adherence as rated by the Morisky Scale (44.1% to 62.7%,
p = 0.023) and Tools for Adherence and Behaviour Screening (23.6% to 57.6%, p = 0.019) in
patients who had one or more risk factors for medication-related problems [46].
It has been shown that a general practice pharmacist is effective at improving the timeliness
of completion of Home Medicine Reviews (HMR) [39]. A complete HMR service includes the
service provided by a GP, an accredited pharmacist (a pharmacist who is licensed to conduct
medication management reviews, including HMRs and Residential Medicine Management
Reviews (RMMR)), and input from a multidisciplinary team from the time the patient is iden-
tified through to the implementation and ongoing monitoring of the medication management
plan and any follow-up service(s) as required [72]. In 2012, Freeman et al reported that a gen-
eral practice pharmacist completed HMRs in a shorter time (within 20 days) than an accred-
ited pharmacist who is external to general practice (within 56 days) [39]. The same study
showed that the number of incomplete medication reviews that were not received by the medi-
cal centre, and HMR reports not reviewed or billed by GPs were significantly reduced from
56% to 6% after including a pharmacist into general practice [39]. Furthermore, this study
demonstrated potential savings of AUD 17,374 per year for general practices from the comple-
tion of HMRs by a general practice pharmacist [39]. Kosari et al in 2020 reported that activities
conducted by two general practice pharmacists saved time for GPs, potentially allowing for
additional GP-patient consultations [60]. In this study, the time saved for GPs was estimated
to be 23.9 hours per month for a full-time pharmacist working 37.5 hours per week [60]. This
study reported that two part-time general practice pharmacists’ activities generated income of
AUD 7000 for general practices over 19 weeks [60]. Furthermore, this study compared the cost
of employing pharmacists against the income generated by them and reported that general
practice pharmacists generated income between AUD 0.61–1.20 per AUD 1.00 of a pharma-
cist’s salary [60].
Several articles have shown that recommendations made by general practice pharmacists to
GPs were frequently accepted (mean acceptance rate: 79.8±10.7%) [39,43,49,50]. It has been
shown that general practice pharmacists’ involvement in clinical activities to support GPs
increased with time working at the practice [52]. It was found that the addition of a general
practice pharmacist improved liaison between the general practice and outreach services in
two articles [57,58]. One article highlighted that the practice pharmacist’s role was intended to
be complementary to and not competitive with that of community pharmacists [58], while the
article by Baker et al highlighted that general practice pharmacists liaised more with hospitals
and other outreach services than accredited pharmacists who worked in conjunction with GPs
[57].
Included articles in this review have not stated any clinical disadvantages of the inclusion of
general practice pharmacists. However, one article reported that the role of community phar-
macists may be duplicated in general practice for smoking cessation and inhaler device educa-
tion, with a subsequent loss of income for the community pharmacy [54]. Overall, the
reported benefits of having a general practice pharmacist are summarised in Table 1.
Perspectives of stakeholders, barriers, and facilitators of the inclusion of pharmacists
into general practices. There were eleven articles (44%) exploring the perspectives of stake-
holders about including pharmacists in general practices [40,41,45,47,48,51,54,57–59,61]. The
studies have indicated that general practice pharmacists were highly accepted into the general
practices by stakeholders, including GPs, pharmacists (accredited and community pharma-
cists), patients, nurses, and practice managers. The main themes identified by the stakeholders
were “benefits of general practice pharmacists”, “barriers and facilitators of the inclusion of
general practice pharmacists”, “pharmacists’ attributes”, “collaboration”, “logistical challenges”
and “sustainability” [40,41,45,47,48,51,54,57–59,61].
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Barriers. There was a number of barriers identified for the inclusion of pharmacists into
general practices in Australia. The main barrier for including pharmacists into general prac-
tices was funding/lack of government support [40,41,45,47,48,51,54,57–59,61]. Logistical chal-
lenges and role clarity were other general impediments identified by the pharmacists and GPs
[40,41,45,47,48,51,54,57–59,61]. A lack of clinic space, lack of time for staff to engage with the
practice pharmacist, and lack of patient time to attend multiple visits were the main logistical
challenges described in the articles [40,47,51,57,59,61].
Medical culture, attitudes and perception of general practice staff and patients were men-
tioned as barriers to the implementation of general practice pharmacists in six articles
[40,45,47,51,58,61]. Underutilisation of general practice pharmacists due to poor awareness of
general practice staff towards the potential services that a practice pharmacist could offer was
discussed in three articles [51,54,57]. The pharmacists have reported that absence of mentors
to guide them in their roles and absence of programs to train them as a general practice phar-
macist were barriers for implementing this practice model [51,54,59,61].
Facilitators. Stakeholders emphasised the GPs’ willingness for collaboration, rapport, com-
munication and team support as the main facilitators for the inclusion of pharmacists in gen-
eral practices [40,41,45,47,49,51,54,57,58]. Pharmacists’ characteristics including proactivity,
good communication skills, clinical competency, credibility and adaptability were other facili-
tators identified in this review [45,47,51,54,57]. The benefit for patients through general prac-
tice pharmacists’ services, such as providing education, was an influencing factor reported by
several articles [40,48,57,59,61]. Only two articles reported having a clearly defined scope of
practice as a factor facilitating the inclusion of general practice pharmacists [40,57]. GPs who
actively recommended the pharmacist to the patient were stated as important to facilitate the
successful implementation of general practice pharmacists [51]. Not surprisingly, remunera-
tion/external funding was another factor that can facilitate the inclusion of general practice
pharmacists [40,45,61]. A study by Freeman et al in 2012 reported that stakeholders thought
that a mix of government and private funding was an appropriate model of remuneration for
pharmacists in general practice [40]. The barriers and facilitators for the inclusion of general
practice pharmacists are summarised in Table 2.
Characteristics, qualifications, and experience of pharmacists in general practice.
Thirteen articles (52%) included in this review mentioned the general practice pharmacists’
characteristics, qualifications, and experience [32,40,42,43,45–47,49,52,54,56,57,60]. In eleven
articles, the pharmacists recruited had accreditation to perform medication reviews
[32,39,40,43,45–47,49,54,57,60]. Freeman et al in 2014 conducted a survey to explore the char-
acteristics of general practice pharmacists Australia-wide and reported that 85% (n = 22) of
Table 1. Benefits of the inclusion of general practice pharmacists.
Benefits
Increase communication and collaboration with GPs [32,40,41,47,48,51,52,54,57,58]
Identify and resolve medication-related problems [43,46,50,52,55,62]
Improve medication adherence [46,49]
Reduce time to complete a medication review [39]
Potential savings in money and time [39,60]
Increase the acceptance of pharmacists’ recommendations by GPs [39,43,49,50]
Improve patient health outcomes [40,48,57,62]
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general practice pharmacists were accredited to conduct medication management reviews,
with 27% (n = 7) having been accredited for 13–15 years, 23% (n = 6) accredited for 1–3 years,
and 19% (n = 5) accredited for 7–9 years [32]. General practice pharmacists’ experience varied
in the included articles in this review. Two articles reported pharmacists’ experience ranged
from 3–31 years [52,54], one article reported that pharmacists’ experience ranged from 3–14
years [60], two articles reported that pharmacists had experience of more than 8 years [46,47],
and one article reported that pharmacists had experience of more than 10 years [49].
Only three articles included in this review reported the educational qualifications of general
practice pharmacists [32,49,57]. One of these articles reported that general practice pharma-
cists had postgraduate qualifications related to clinical pharmacy (clinical pharmacy is a field
in which pharmacists provide direct patient care to optimise medication use, often in the hos-
pital setting) [49]. One quantitative descriptive study conducted Australia-wide reported that
58% (n = 15) of general practice pharmacists had postgraduate qualifications: coursework mas-
ters (27% (n = 7)), graduate diploma (23% (n = 6)) or a research doctorate (15% (n = 4)) [32].
Furthermore, one article reported accredited pharmacists’ opinions about desirable character-
istics of pharmacists (qualifications, skills, experience, training) to work effectively in general
practice: prior experience as a hospital pharmacist, communication skills, problem solving
skills, Information Technology (IT) skills and understanding pharmacoeconomics [57]. The
reported characteristics, qualifications, experience, skills, and desirable special training of gen-
eral practice pharmacists are summarised in Table 3.
Table 2. Barriers and facilitators for the inclusion of general practice pharmacists in Australia.
Barriers Facilitators
Funding/lack of government support [40,41,45,47,48,51,54,57–59,61] Willingness of collaboration (rapport, communication, and team support)
[40,41,45,47,49,51,54,57,58]Role clarity [40,41,45,47,48,51,54,57–59]
Logistical challenges (office space, lack of resources and time)
[40,47,51,57,59,61]
Pharmacists’ characteristics [45,47,51,54,57]
Lack of awareness of pharmacists’ activities and underutilisation
[51,54,57]
Clearly defined scope of practice [40,57]
Benefits for patients and better patient outcomes [40,48,57,59,61]
Medical culture, perception, and attitudes [40,45,47,51,58,61] Recommendation by GPs to patients [51]
Lack of mentors [51,54,59,61] Remuneration/external funding [40,45,61]
�GP-General Practitioner.
https://doi.org/10.1371/journal.pone.0258674.t002




Accreditation Accreditation to perform medication management reviews [32,39,40,43,45–
47,49,54,57,60]
Experience Minimum 3 years of experience [46,47,49,52,54,60], prior hospital experience
(desirable) [57]
Educational qualifications Postgraduate qualifications [32,49,57]
Special training Desirable training: Introductory modules by PSA, GP software, spirometry, mental
health, online asthma counselling, and motivational interviewing and health
coaching [57]
One article stated that pharmacist had completed training related to smoking
cessation [56]
Skills Communication skills, problem solving skills, IT skills, understanding
pharmacoeconomics [57]
�PSA-Pharmaceutical Society of Australia, GP-General Practitioner, IT-Information Technology.
https://doi.org/10.1371/journal.pone.0258674.t003
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Discussion
Over the past 20 years, the role of general practice pharmacists has been expanding worldwide.
This review included articles with various methodologies, which explored factors related to the
general practice pharmacist model in Australia. It adds a valuable insight on the overall view of
pharmacists being embedded into general practices in Australia over the last decade.
Benefits and activities of general practice pharmacists
Overall, our findings indicated that the inclusion of pharmacists in Australian general practices
benefited patients by improving medication safety, mainly through resolving medication-
related problems [40,43,46,48–50,52,55,57,62]. Increasing communication between general
practice pharmacists and GPs is critical in order to facilitate the effective functioning of pri-
mary care services in the context of growing demand [73]. Our findings indicated that the
inclusion of pharmacists in general practices can increase communication with general prac-
tice team members [32,40,41,47,48,51,52,54,57,58]. Moreover, general practice pharmacists’
recommendations were highly accepted by GPs, which demonstrates rapport between these
two professionals [39,43,49,50]. These findings are supported by international studies con-
ducted in the UK and Canada [9,13,20,25].
There are mixed views on the liaison between community pharmacists and general practice
pharmacists. In this review, it was shown that a key priority of the general practice pharmacist
was to act as a conduit between community pharmacy, hospital pharmacy, and the general
practice [57,58]. Community pharmacists appeared less enthusiastic towards pharmacists
working in general practice according to one Australian article [54], while international studies
have reported mixed views on the relationship between community pharmacists and general
practice pharmacists: this includes a good rapport, and significant tensions stemming from
professional hierarchy and competing business-related interests [9,74,75]. However, there is a
knowledge gap in examining the impact of liaison between community pharmacists and gen-
eral practice-based pharmacists, mainly around HMRs, smoking cessation, and lifestyle advice
[54,76]. Therefore, further studies are required to explore collaboration between community
pharmacists and general practice pharmacists.
The general practice pharmacist can engage in various activities, including medication
safety initiatives such as clinical audits, medication management, education, and administra-
tive work to improve patient health outcomes in general practices [32,40,42,44,46,48–53,55–
57,62]. However, the primary function of general practice pharmacists reported by the major-
ity of the articles was medication management reviews, in line with the stakeholders’ desired
function of practice pharmacists [32,39,43,46,49–51,62]. This result is expected because HMRs
and RMMRs are the only government-remunerated cognitive services that a pharmacist can
conduct outside the community pharmacy in Australia [77]. Even though these activities are
consistent with the international literature, general practice pharmacists’ activities are rela-
tively limited by the scope of practice in Australia [9,13,78]. In particular, Australian pharma-
cists are unable to prescribe like general practice pharmacists in the UK and Canada, and are
therefore very reliant on GPs adopting their recommendations [11,23,43,39,43,49,50,79]. Posi-
tively, however, the general practice pharmacists’ recommendations were highly accepted by
GPs [39,43,49,50].
The activities that could be performed by a general practice pharmacist may save the time
of GPs and generate income for the practice. A systematic review has reported that advanced
pharmacy services appear to be cost-effective when delivered in community and primary care
settings, but not in domiciliary settings [80]. A recent Irish study has reported that activities
(medication reviews and involvement in the repeat prescribing process) by three general
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practice pharmacists working for 10 hours per week over 26 weeks saved approximately EUR
57 000 per year for general practices [81]. In Australia, as elsewhere, there is limited data on
cost-benefits of the role of general practice pharmacists. The potential time saved for GPs by
tasks being undertaken by part-time general practice pharmacists in one study was estimated
to be 23.9 hours per month for a full-time pharmacist working 37.5 hours per week [60]. Based
on the findings of this review, it is recommended to further evaluate clinical and non-clinical
activities, and the cost-benefits of general practice pharmacists, with robust methodologies.
Barriers and facilitators of the inclusion of general practice pharmacists
The general practice pharmacist model has been well accepted by stakeholders
[40,41,45,47,48,51,54,57–59,61]. This systematic review has highlighted several barriers,
including lack of resources (funding/lack of government support, logistic challenges), lack of
role definition, and lack of mentoring/training. Our results are broadly consistent with inter-
national studies regarding the barriers that pharmacists face when attempting to integrate into
primary care teams [9,21,82,83]. Appropriate planning and preparation can be utilised to miti-
gate the identified barriers [82]. Identified factors that enhanced the inclusion of general prac-
tice pharmacists were willingness to collaborate, team support, pharmacists’ characteristics,
recommendation by GPs to patients, a clearly defined scope of practice and proven benefits
for patients [40,41,45,47,48,51,54,57–59,61]. Positive inclusion of pharmacists into general
practices appeared to be greatly reliant on the individual characteristics of the pharmacists.
Pharmacists who were pro-active, adaptive, and confident were more likely able to facilitate
their inclusion in Australian general practices. These findings are compatible with studies con-
ducted in Canada [9,21,82].
This review has revealed that there is sufficient evidence to explain barriers and facilitators
for the inclusion of Australian general practice pharmacists [40,41,45,47,48,51,54,57–59,61].
Unfortunately, these barriers are persisting, and it suggests that actions made to minimise bar-
riers are still lacking. The findings of the review provide a better understanding of the barriers
and facilitators when developing strategies to ensure pharmacists are successfully included in
general practice teams.
Qualifications and training of general practice pharmacists
Accreditation to perform medication reviews, postgraduate qualifications, experience as a reg-
istered pharmacist, and specific skills such as communication and analytical skills, and training
were the main desirable characteristics of general practice pharmacists in the articles included
in this review [32,40,42,43,45–47,49,52,54,56,57,60]. The general practice pharmacists in Aus-
tralia have not received formal training or guidelines before their employment. This contrasts
with the inclusion of clinical pharmacists in general practices in the UK and Canada. In the
UK, a government-funded general practice pharmacist training pathway was introduced for
pharmacists employed in general practice. This consisted of an 18-month mandatory training
program which provided a combination of study days, peer-learning groups, assessments, and
access to three support functions—an education supervisor (offering individualised educa-
tional support), a GP clinical supervisor (based in practice, offering day-to-day clinical sup-
port), and a clinical mentor (an experienced clinical pharmacist) [10]. In Canada, the
IMPACT training session was introduced as a transitional programme for pharmacists enter-
ing family practice to provide guidance and strategies. In addition, the “Adapting pharmacists’
skills and Approaches to maximize Patient’s drug Therapy effectiveness” (ADAPT) educa-
tional program was developed to provide a standard approach to medication assessment, team
collaboration, patient assessment, evidence-based decision making and documentation,
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facilitated through an e-learning program for pharmacists in family health teams [20,84]. Simi-
lar models are desperately needed in Australia. Recently, the PSA has developed introductory
modules for pharmacists wishing to work in general practices, focusing on the practical aspects
of working as a general practice pharmacist [85]. However, the PSA training modules only
provide an overview of the core knowledge and skills required by general practice pharmacists.
A Delphi study has reported 26 general practice pharmacist activities as educational needs
in Australia, which was consistent with the themes in international studies [86]. This study has
highlighted those activities related to medication management, chronic disease management,
research, patient examination and screening, and audit and quality assurance were the major
educational needs of general practice pharmacists [86]. By defining the core needs of the role,
appropriate training and education programs can be developed for general practice pharma-
cists. Our findings support that comprehensive training programs are required for general
practice pharmacists in Australia, as identified by Benson et al in [86].
Knowledge gap
Whilst the literature to date demonstrates several studies exploring the general practice phar-
macist model in Australia, there is still limited evidence regarding certain areas. These include:
awareness of stakeholders towards the activities that general practice pharmacists could per-
form, cost-benefits of including general practice pharmacists, interprofessional collaboration
after including pharmacists into general practice teams, training and education needs of gen-
eral practice pharmacists, guidelines/recommendations to utilise pharmacists in the general
practice setting, and liaison of general practice pharmacists with community pharmacists and
other out-reach services such as hospital pharmacies and aged-care facilities. While a limited
number of studies indicated that general practice pharmacists’ activities improved patients’
health outcomes, evidence based on the use of robust methodologies is still lacking. Only one
recent study, published outside of the search period of this review, utilised a randomised con-
trolled trial [87]. This article reported that general practice pharmacists’ medication manage-
ment services reduced the number of unplanned hospital admissions for patients recently
discharged from hospitals who were prescribed five or more long-term medicines or had a pri-
mary discharge diagnosis of congestive heart failure or exacerbation of chronic obstructive
pulmonary disease [87]. The estimated incremental net cost-benefit of the general practice
pharmacist-led medication management services was AUD 5072 per patient, with a benefit-
cost ratio of 31:1 [87]. As such, there is a need for more randomised controlled trials to explore
the patient outcomes related to clinical activities that a pharmacist can perform in general
practice.
Strengths and limitations
A strength of this systematic review was the inclusion of studies with various methodologies,
including quantitative, qualitative and mixed-methods studies. This allowed a comprehensive
and robust characterisation and evaluation of aspects of the implementation of general
practice pharmacists in Australia. Moreover, abstract screening and data extraction were com-
pleted through compliance with best practice. Another strength of this review was contacting
original investigators to obtain additional research information to improve the accuracy of the
review.
The study has several limitations that constrain our conclusions. First, this review found a
relatively small number of relevant studies. Only 25 studies were identified with various meth-
odologies [32,39–62], which led to the choice of a narrative synthesis approach for data analy-
sis. Second, there is the potential of researcher bias in the evaluation, although two reviewers
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independently assessed the articles. Third, the role of general practice pharmacists is relatively
new in Australia; studies have been conducted in a limited number of general practices that
believed in value of the inclusion of pharmacists in general practice. Therefore, the findings
related to clinical disadvantages of the inclusion of general practice pharmacists may not be
reported in the included articles in this review and the findings may not be generalisable to all
Australian general practices if this model is rolled out in the future.
Study implications
The study has several implications. There is a need to:
• Utilise robust methodologies to assess clinical/non-clinical activities of general practice
pharmacists.
• Act on the barriers and facilitators for the successful implementation of general practice
pharmacists, especially those relating to funding and training.
• Explore further in the areas where there are knowledge gaps related to the general practice
pharmacist model identified through this review.
The findings of this systematic review will be useful for researchers, policy makers, and
stakeholders to strengthen the role of general practice pharmacists in Australia. Furthermore,
our findings will be beneficial for readers who wish to implement a team-based primary care
model in their countries where the inclusion of pharmacists into primary care teams is not
established yet.
Conclusion
This systematic review has summarised the characteristics, activities, benefits, barriers, and
areas requiring further exploration relating to pharmacists working in general practice in Aus-
tralia. General practice pharmacists are well accepted by stakeholders; they can engage in a
range of clinical/non-clinical activities to benefit patients and general practices. This review
has revealed that more actions are required on the factors that posed a challenge to the inclu-
sion of pharmacists in general practice. Furthermore, this review has suggested more robust
research to explore the patient and economic outcomes related to clinical activities that a phar-
macist can perform in general practice, as a foundation to developing an appropriate and sus-
tainable funding model.
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